MNG1098
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.399
- APICAL_SURFACE+0.338
- INTERFERON_GAMMA_RESPONSE+0.300
- KRAS_SIGNALING_DN+0.294
- INTERFERON_ALPHA_RESPONSE+0.274
- INFLAMMATORY_RESPONSE+0.247
- MYOGENESIS+0.185
- PANCREAS_BETA_CELLS+0.151
- IL6_JAK_STAT3_SIGNALING+0.092
- KRAS_SIGNALING_UP+0.020
Top 10 suppressed
- MYC_TARGETS_V1-0.650
- PROTEIN_SECRETION-0.597
- MYC_TARGETS_V2-0.588
- UNFOLDED_PROTEIN_RESPONSE-0.577
- OXIDATIVE_PHOSPHORYLATION-0.571
- MTORC1_SIGNALING-0.553
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.504
- ANDROGEN_RESPONSE-0.501
- G2M_CHECKPOINT-0.481
- E2F_TARGETS-0.480
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG882 | — | — | 0.959 |
| 2 | MNG450 | — | — | 0.943 |
| 3 | R96 | — | — | 0.920 |
| 4 | MNG1159 | — | — | 0.919 |
| 5 | MNG1248 | — | — | 0.912 |
| 6 | TCGA-49-AAR4-01A-12R-A41B-07 | — | cohortA1 | 0.911 |
| 7 | SRR1421093 | GTEX | — | 0.909 |
| 8 | SRR1337431 | GTEX | — | 0.908 |
| 9 | SRR8942994 | — | — | 0.907 |
| 10 | SRR650162 | — | — | 0.905 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.399 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.338 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.294 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.274 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.247 | Idelalisib | — uncovered |
| MYOGENESIS | 0.185 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.151 | Cobimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.092 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.020 | Inavolisib | — uncovered |